Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N05 PSYCHOLEPTICS
N05B ANXIOLYTICS
N05BA Benzodiazepine derivatives
N05BA09 Clobazam
D01253 Clobazam (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Anticonvulsants
Gamma-aminobutyric Acid (GABA) Augmenting Agents
Benzodiazepines
Clobazam
D01253 Clobazam (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
113 Antiepileptics
1139 Others
D01253 Clobazam (JAN/USAN/INN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01567 GABA-A receptor agonist
D01253 Clobazam
DG01914 Anxiolytics, benzodiazepine derivatives
D01253 Clobazam
DG03199 Antiepileptic agent
DG02036 Benzodiazepine derivative, antiepileptic
D01253 Clobazam
Metabolizing enzyme substrate
DG01639 CYP2C19 substrate
D01253 Clobazam
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D01253 Clobazam
Drug classes [BR:br08332]
Neuropsychiatric agent
DG03199 Antiepileptic agent
D01253 Clobazam
Target-based classification of drugs [BR:br08310]
Ion channels
Ligand-gated ion channels
GABA (ionotropic)
GABR
D01253 Clobazam (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D01253
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D01253
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D01253
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D01253
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D01253
Narcotics and psychotropics in Japan [br08308.html]
Psychotropics by Cabinet order Article 3 (78 substances)
D01253